COMPANY PROFILE

ZS Pharma

Develops ion trap therapies for the treatment of life-threatening medical conditions such as hyperkalemia and liver diseases

Coppell, United StatesFounded 2008Biotech & Life Sciences

Valuation $330M Market cap · 2014

About ZS Pharma

ZS Pharma, a subsidiary of AstraZeneca, specializes in developing and commercializing innovative treatments for hyperkalemia, a condition characterized by elevated potassium levels in the blood. The company primarily serves healthcare providers and patients in the pharmaceutical market. ZS Pharma's core product, Lokelma, is designed to treat hyperkalemia by binding potassium in the gastrointestinal tract, thereby reducing its absorption into the bloodstream. The business model focuses on research and development, regulatory approval, and commercialization of pharmaceutical products. Revenue is generated through product sales, partnerships, and licensing agreements. ZS Pharma operates in a highly regulated market, ensuring compliance with stringent healthcare standards and data privacy obligations.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 2008
Headquarters: Coppell, United States
Listing: IPO 2014
Employees: 44
Open positions: None listed
Dealroom signal: 71.4/100
Industry: Health
Sub-industry: Pharmaceutical
Sector: Biotech & Life Sciences, Risk Management, Biotechnology, Patient Care, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

8 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITIONOther financing	Nov 2015	$2.7B	—	AstraZeneca	—
POST IPO DEBTDebt	Jul 2014	$20M	—	Undisclosed	—

Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

ZS Pharma website traffic

Latest recorded traffic for ZS Pharma is 0 monthly website visits.

Latest monthly visits0

Monthly website visitsApr 2016–May 2020

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
EQEquiscriptEquiscript helps Safety Net Providers grow their 340B Pharmacy	North Charleston, United States	Operational	71	$1M	$4M
KPKiadis PharmaEngaged in the clinical development and commercialization of cell-based immunotherapy products for treatment of blood cancer and blood disorders	Amsterdam, Netherlands	Acquired
DIDiaCartaImproving patient care through novel precision molecular diagnostics: CE/IVD marked tests are available for detection of KRAS	Hayward, United States	Operational
SMSadra MedicalFocused on developing minimal invasive alternatives to surgical valve replacement and improve patient care	Campbell, United States	Acquired
FCFrensenius Vascular CareFresenius Vascular Care develops and manages specialty outpatient vascular centers that deliver vascular care services.	Easttown Township, United States	Operational
RSRainTree Oncology ServicesRainTree Oncology Services	San Diego, United States	Acquired
OPOmthera PharmaceuticalsDevelops therapies for patients with elevated triglyceride levels and increased risk of cardiovascular disease	Princeton, United States	Acquired
DIDiagnotesConnecting Health Care Teams For More Effective Communication \| Diagnotes \| Diagnotes \| Patient Care. Anywhere.	Indianapolis, United States	Operational